Unknown

Dataset Information

0

Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis.


ABSTRACT:

Background

Neoadjuvant chemotherapy is increasingly used to treat locally advanced (T3-4 Nx-2 M0) colon cancer due to its potential advantages over the standard approach of upfront surgery. The primary objective of this systematic review and meta-analysis was to analyse data from comparative studies to assess the impact of neoadjuvant chemotherapy on oncological outcomes.

Methods

A systematic review was conducted by searching the MEDLINE and Scopus databases. The search encompassed RCTs, propensity score-matched studies, and controlled prospective studies published up to 1 April 2023. As a primary objective, overall survival and disease-free survival were compared. As a secondary objective, perioperative morbidity, mortality, and complete resection were compared using the DerSimonian and Laird models.

Results

A total of seven studies comprising a total of 2120 patients were included. Neoadjuvant chemotherapy was associated with a reduction in the hazard of recurrence (HR 0.73, 95% c.i. 0.59 to 0.90; P = 0.003) and death (HR 0.67, 95% c.i. 0.54 to 0.83; P < 0.001) compared with upfront surgery. Additionally, neoadjuvant chemotherapy was significantly associated with higher 5-year overall survival (79.9% versus 72.6%; P < 0.001) and disease-free survival (73.1% versus 64.5%; P = 0.028) rates. No significant differences were observed in perioperative mortality (OR 0.97, 95% c.i. 0.28 to 3.33), overall complications (OR 0.95, 95% c.i. 0.77 to 1.16), or anastomotic leakage/intra-abdominal abscess (OR 0.88, 95% c.i. 0.60 to 1.29). However, neoadjuvant chemotherapy was associated with a lower risk of incomplete resection (OR 0.70, 95% c.i. 0.49 to 0.99).

Conclusion

Neoadjuvant chemotherapy is associated with a reduced hazard of recurrence and death, as well as improved overall survival and disease-free survival rates, compared with upfront surgery in patients with locally advanced colon cancer.

SUBMITTER: Aliseda D 

PROVIDER: S-EPMC10881053 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis.

Aliseda Daniel D   Arredondo Jorge J   Sánchez-Justicia Carlos C   Alvarellos Alicia A   Rodríguez Javier J   Matos Ignacio I   Rotellar Fernando F   Baixauli Jorge J   Pastor Carlos C  

The British journal of surgery 20240101 2


<h4>Background</h4>Neoadjuvant chemotherapy is increasingly used to treat locally advanced (T3-4 Nx-2 M0) colon cancer due to its potential advantages over the standard approach of upfront surgery. The primary objective of this systematic review and meta-analysis was to analyse data from comparative studies to assess the impact of neoadjuvant chemotherapy on oncological outcomes.<h4>Methods</h4>A systematic review was conducted by searching the MEDLINE and Scopus databases. The search encompasse  ...[more]

Similar Datasets

| S-EPMC3999636 | biostudies-other
| S-EPMC10798774 | biostudies-literature
| S-EPMC8318625 | biostudies-literature
| S-EPMC8101236 | biostudies-literature
| S-EPMC9600337 | biostudies-literature
| S-EPMC7773852 | biostudies-literature
| S-EPMC10203550 | biostudies-literature
| S-EPMC9495441 | biostudies-literature
| S-EPMC10099833 | biostudies-literature
| S-EPMC7786973 | biostudies-literature